Media
This content is intended for non-U.S. journalists. U.S. journalists, please visit the U.S. Media Room
ZOMETA® (zoledronic acid)
- www.zometa.com
(For Non U.S. Health Care Professionals Only)
ZOMETA CONTACT
ZOMETA® is indicated for the prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone or tumour-induced hypercalcameia) in patients with advanced malignancies involving bone.
- Treatment of tumor-induced hypercalcemia
This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.
ZOMETA Press Releases
ZOMETA Images
-
08-Dec-2009
ZOMETA Product Shot (JPG)
ZOMETA Additional Materials
-
21-Dec-2009
Global ABCSG-12 Backgrounder -
21-Dec-2009
Global ABCSG-12 Trial Design -
21-Dec-2009
Zometa Breast Cancer Recurrence Fact Sheet -
21-Dec-2009
Zometa Breast Cancer and Distant Recurrence Fact Sheet -
30-Nov-2009
Zometa Breast Cancer Backgrounder -
15-June-2009
ZOMETA Fact Sheet -
11-June-2009
Cancer: Its Effect on Bones Fact Sheet -
20-May-2009
Bone Metastases Backgrounder
SEARCH OUR WEBSITES
ABOUT NOVARTIS ONCOLOGY
We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.